{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:54:59Z","timestamp":1782258899199,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":3243,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:p>We reviewed 42 cases of cefepime\u2010induced neurotoxicity and 12 cases of ceftazidime\u2010induced neurotoxicity from the literature and our institution. Clinical characteristics and timing of diagnosis were examined. Common findings were confusion with temporospatial disorientation (96% of patients), myoclonus (33%), and seizures (13%). These neurologic disorders frequently are encountered in uremic and elderly patients, who often are in a confused state when they visit their physician. The risk of delayed diagnosis was greater with cefepime than ceftazidime neurotoxicity. The median interval between symptom onset and diagnosis of cefepime versus ceftazidime neurotoxicity was 5 and 3 days, respectively (p=0.005). Delayed diagnosis of cefepime neurotoxicity may be due to lack of awareness of the adverse effect. Data gathered since these two broad\u2010spectrum antibiotics were first marketed underscore the potential for neurologic adverse events secondary to their administration. Thus, clinicians' awareness must be increased so that the time between symptom onset and diagnosis can be reduced.<\/jats:p>","DOI":"10.1592\/phco.23.3.369.32100","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T07:27:08Z","timestamp":1084260428000},"page":"369-373","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Retrospective Review of Neurotoxicity Induced by Cefepime and Ceftazidime"],"prefix":"10.1002","volume":"23","author":[{"given":"Kai Ming","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Chun","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Che\u2010Fai","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Yuk\u2010Hwa","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Kam\u2010Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00110-6"},{"key":"e_1_2_1_3_2","first-page":"711","volume-title":"Meyler's side effects of drugs","author":"Neftel KA","year":"1996"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-1-92"},{"key":"e_1_2_1_5_2","first-page":"1629","article-title":"Neurotoxicity of antibiotics","volume":"51","author":"Goldner JC","year":"1968","journal-title":"Minn Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.236"},{"key":"e_1_2_1_7_2","first-page":"251","article-title":"Drug\u2010induced myoclonus","volume":"43","author":"Klawans HL","year":"1986","journal-title":"Adv Neurol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.26105"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.9.2265"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1756"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.11.2153"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0987-7053(00)00234-3"},{"key":"e_1_2_1_13_2","first-page":"554","article-title":"Nonconvulsive status epilepticus secondary to adjusted cefepime doses in patients with chronic renal failure","volume":"20","author":"Saurina A","year":"2000","journal-title":"Nefrologia"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00767-7"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-001-1170-9"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-11-200112040-00027"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1988.00520330010002"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6652.858-a"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.12.2008"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1991.tb04302.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.4.333"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420050158014"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/089686089401400424","article-title":"Neurotoxicity associated with intraperitoneal ceftazidime therapy in a CAPD patient","volume":"14","author":"Lye WC","year":"1994","journal-title":"Perit Dial Int"},{"key":"e_1_2_1_24_2","first-page":"681","volume-title":"Epilepsy: a comprehensive textbook","author":"Williamson PD","year":"1997"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.1999.11754213"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90326-9"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91476-O"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.2.187"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039050-00003"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000169402"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197601152940306"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5706.394"},{"key":"e_1_2_1_33_2","first-page":"1919","volume-title":"Neurology in clinical practice, 3rd ed, vol 2","author":"Riley DE","year":"2000"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.23.3.369.32100","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.23.3.369.32100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:00:28Z","timestamp":1761066028000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.23.3.369.32100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1592\/phco.23.3.369.32100"],"URL":"https:\/\/doi.org\/10.1592\/phco.23.3.369.32100","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}